Quick Answer
Skye Bioscience, Inc. reported Diluted EPS of $1.41 per share (loss) for fiscal year 2025.
Skye Bioscience, Inc. Diluted EPS — Annual History
| Fiscal Year | Diluted EPS | YoY Change |
|---|---|---|
| 2025 | -$1.41 | -93.2% |
| 2024 | -$0.73 | +86.4% |
| 2023 | -$5.37 | +38.8% |
| 2022 | -$8.77 | -43750.0% |
| 2021 | -$0.02 | +33.3% |
| 2020 | -$0.03 | +40.0% |
| 2019 | -$0.05 | +68.8% |
| 2018 | -$0.16 | -45.5% |
| 2017 | -$0.11 | +35.3% |
| 2016 | -$0.17 | — |
Quarterly Diluted EPS
| Quarter Ending | Diluted EPS | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | -$0.32 | -220.0% | +27.3% |
| June 30, 2025 | -$0.44 | -120.0% | -57.1% |
| March 31, 2025 | -$0.28 | -55.6% | -180.0% |
| September 30, 2024 | -$0.10 | +96.8% | +50.0% |
| June 30, 2024 | -$0.20 | +75.0% | -11.1% |
| March 31, 2024 | -$0.18 | +86.9% | +94.3% |
| September 30, 2023 | -$3.17 | -100.6% | -296.2% |
| June 30, 2023 | -$0.80 | -7900.0% | +41.6% |
- Skye Bioscience, Inc. showed a decrease of -93.2% in Diluted EPS compared to the prior fiscal year.
- Over the 2016–2025 period, Skye Bioscience, Inc.’s diluted eps has declined by 729.4% (from $0.17 per share (loss) to $1.41 per share (loss)).
- The most recent figure is from Skye Bioscience, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 10, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: